Bergamo

• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended recruitment
  2023-509576-42-00 5 2019-02-21 Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended recruitment
  2024-511204-16-00 5 2019-01-23 Metastatic breast cancer
• Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended recruitment
  2023-505376-30-00 4 2018-10-30 BRAF V600 mutation–positive unresectable or metastatic melanoma
• Study to determine safety, efficacy and tolerability of Venetoclax in combination with Fludarabine, Citarabine and Idarubicin to achieve "th … Ended recruitment
  2023-510517-26-00 9 2018-10-26 Acute Myeloid Leukemia
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient … Ended recruitment
  2023-505222-34-00 7 2018-04-23 Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended recruitment
  2023-503438-40-00 7 2017-10-05 Relapsed/Refractory Multiple Myeloma
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C … Ended recruitment
  2023-507500-31-00 10 2017-08-22 Advanced or metastatic Non-small cell lung cancer (NSCLC)
• Clinical trial with Ibrutinib and Venetoclax for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Ended recruitment
  2024-514686-19-00 4 2017-03-10 Relapsed or Refractory Chronic Lymphocytic Leukemia
• Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect … Ended recruitment
  2023-510434-83-00 6 2016-10-17 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
• A study for patients who have completed a prior global Novartis sponsored ceritinib (LDK378) study and are judged by the investigator to ben … Ended recruitment
  2024-511040-58-00 6 2016-01-12 non small cell lung cancer
• A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl … Ended recruitment
  2023-506524-82-00 5 2015-10-21 Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Long-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Ended recruitment
  2024-512413-40-00 4 2013-03-08 Chronic myeloproliferative neoplasm
• A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted
  2023-505840-20-00 9 2024-08-16 B-Cell Acute Lymphoblastic Leukaemia
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted
  2024-515152-20-00 4 2023-03-02 Stage III and high-risk stage II resected colon cancer patients.
• A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted
  2023-506136-32-00 9 2020-10-12 Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
• A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer Ended
  2024-515607-19-00 1 2025-03-19 Patients with suspected clear cell renal cell carcinoma (ccRCC)
• A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer Ended
  2024-515608-38-00 1 2025-03-19 Patients with prostate cancer with: -suspected metastasis who are cand

Showing 289–312 of 373 trials